Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06046248
PHASE2

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Sponsor: Northside Hospital, Inc.

View on ClinicalTrials.gov

Summary

This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

Official title: Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2024-01-29

Completion Date

2027-12-31

Last Updated

2025-10-30

Healthy Volunteers

No

Interventions

DRUG

Belumosudil

200mg PO QD x 24 cycles (28-day cycle)

DRUG

Rituximab

375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses

Locations (1)

Northside Hospital

Atlanta, Georgia, United States